Review Article
AXL as a Target in Breast Cancer Therapy
Table 1
AXL-targeted therapies currently in clinical trials in the U.S.
| | Therapeutic | Clinical trial | Phase | Disease |
| | Small molecule inhibitor | | | | | AXL selective | | | | | BGB324/R428/bemcentinib | NCT02424617 | Phase 1/2 | NSCLC | | NCT02488408 | Phase 1/2 | Acute myeloid leukemia, myelodysplastic syndrome | | NCT02872259 (active) | Phase 1/2 | Melanoma | | NCT02922777 (active) | Phase 1 | NSCLC | | NCT03184558 (completed) | Phase 2 | ∗TNBC, inflammatory BC | | NCT03184571 (active) | Phase 2 | NSCLC, lung adenocarcinoma, metastatic lung cancer | | NCT03649321 (active) | Phase 1/2 | Pancreatic | | NCT03654833 (active) | Phase 2 | Mesothelioma | | NCT03824080 (active) | Phase 2 | Acute myeloid leukemia, myelodysplastic syndrome | | NCT03965494 | Early phase 1 | Glioblastoma | | SLC-391/SLC 0211 | NCT03990454 | Phase 1 | Solid tumors | | TP-0903 | NCT02729298 (active) | Phase 1 | Solid tumors | | NCT03572634 (active) | Phase 1/2 | Chronic lymphocytic leukemia, small lymphocytic lymphoma | | Dual AXL/MER | | | | | INCB081776 | NCT03522142 (active) | Phase 1 | Solid tumors | | ONO-7475 | NCT03176277 (active) | Phase 1 | Acute leukemia | | Antibody-based | | | | | Antibody-drug conjugate | | | | | BA3011/CAB-AXL-ADC | NCT03425279 (active) | Phase 1/2 | Solid tumors | | Enapotamab vedotin/HuMax-AXL-ADC/AXL-107-MMAE | NCT02988817 (active) | Phase 1/2 | Solid tumors | | Monoclonal antibody | | | | | BGB149 | NCT03795142 (active) | Early phase 1 | Healthy volunteers | | Anti-AXL Fc fusion protein | | | | | AVB-S6-500 | NCT03607955 | Phase 1 | Ovarian, fallopian, peritoneal | | | NCT03639246 (active) | Phase 1/2 | Ovarian | | NCT04004442 | Phase 2 | Urothelial carcinoma | | NCT04019288 | Phase 1/2 | Ovarian, fallopian, peritoneal | | NCT04042623 | Phase 2 | IgA nephropathy | | CAR T-based therapy | | | | | CCT301-38 | NCT03393936 (active) | Phase 1/2 | Renal cell carcinoma |
|
|
